ACC 2022 – Complete Trial QoL: Complete Revascularization in STEMI

The COMPLETE study has shown complete revascularization in STEMI reduces cardiovascular mortality or new AMI, which generated a change in ACC/AHA 2021 revascularization guidelines. However, its impact on quality of life is yet to be studied. 

ACC 2022 - Estudio Complete Trial QoL: Revascularización completa en el SCACEST

The aim of this prespecified analysis of the COMPLETE study is to determine whether complete revascularization improves quality of life free from angina compared against a culprit-only revascularization strategy.

The Seattle Angina Questionnaire (SAQ) was used at randomization, 6 months and final visit (mean 3 years). Assessed outcomes included angina related and proportion of patients free from angina events. 

In STEMI patients with multivessel disease both patients with complete revascularization and culprit only revascularization improved angina related quality of life. At 3-year followup, there was a higher proportion of patients free from angina in the complete revascularization group, with NNT 31 patients.

Read also: ACC 2022 | VALOR-HCM: Mavacamten in Adults with Symptomatic Obstructive HCM Eligible for Septal Reduction Therapy

The subgroup analysis showed the greatest impact: benefit was confined to those with a non-culprit lesion ≥80%.

Conclusions

Complete revascularization in STEMI improves quality of life free from angina compared against culprit only revascularization, a benefit that adds to the one previously showed, the reduction of major cardiovascular events. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board, SOLACI.org

Original Title: Complete trail Qol: Complete trail Quality of life  

Reference: Presentado por Dr. Shamir R. Mehta en las sesiones cientificas anuales del American College of Cardiology (ACC 2022), Washington, Abril 2, 2022.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....